X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUN PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUN PHARMA CADILA HEALTHCARE/
SUN PHARMA
 
P/E (TTM) x 32.8 25.9 126.7% View Chart
P/BV x 6.1 3.8 161.2% View Chart
Dividend Yield % 0.8 0.6 127.0%  

Financials

 CADILA HEALTHCARE   SUN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
SUN PHARMA
Mar-17
CADILA HEALTHCARE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs460842 54.6%   
Low Rs305572 53.3%   
Sales per share (Unadj.) Rs92.1131.6 70.0%  
Earnings per share (Unadj.) Rs14.832.7 45.3%  
Cash flow per share (Unadj.) Rs18.538.0 48.7%  
Dividends per share (Unadj.) Rs3.203.50 91.4%  
Dividend yield (eoy) %0.80.5 169.1%  
Book value per share (Unadj.) Rs68.0152.7 44.5%  
Shares outstanding (eoy) m1,023.742,399.26 42.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.25.4 77.3%   
Avg P/E ratio x25.821.6 119.4%  
P/CF ratio (eoy) x20.718.6 111.1%  
Price / Book Value ratio x5.64.6 121.5%  
Dividend payout %21.610.7 201.8%   
Avg Mkt Cap Rs m391,5811,696,877 23.1%   
No. of employees `00016.917.5 96.2%   
Total wages/salary Rs m15,00249,023 30.6%   
Avg. sales/employee Rs Th5,594.518,028.3 31.0%   
Avg. wages/employee Rs Th890.12,798.8 31.8%   
Avg. net profit/employee Rs Th899.94,479.5 20.1%   
INCOME DATA
Net Sales Rs m94,295315,784 29.9%  
Other income Rs m1,2866,232 20.6%   
Total revenues Rs m95,581322,016 29.7%   
Gross profit Rs m19,036100,893 18.9%  
Depreciation Rs m3,75012,648 29.7%   
Interest Rs m4503,998 11.3%   
Profit before tax Rs m16,12290,479 17.8%   
Minority Interest Rs m3380-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,28912,116 10.6%   
Profit after tax Rs m15,16878,462 19.3%  
Gross profit margin %20.231.9 63.2%  
Effective tax rate %8.013.4 59.7%   
Net profit margin %16.124.8 64.7%  
BALANCE SHEET DATA
Current assets Rs m60,223329,537 18.3%   
Current liabilities Rs m53,058178,870 29.7%   
Net working cap to sales %7.647.7 15.9%  
Current ratio x1.11.8 61.6%  
Inventory Days Days7079 88.4%  
Debtors Days Days8883 105.9%  
Net fixed assets Rs m72,984204,766 35.6%   
Share capital Rs m1,0242,399 42.7%   
"Free" reserves Rs m68,576363,997 18.8%   
Net worth Rs m69,600366,397 19.0%   
Long term debt Rs m24,68414,361 171.9%   
Total assets Rs m152,207614,102 24.8%  
Interest coverage x36.823.6 155.8%   
Debt to equity ratio x0.40 904.9%  
Sales to assets ratio x0.60.5 120.5%   
Return on assets %10.313.4 76.4%  
Return on equity %21.821.4 101.8%  
Return on capital %17.924.8 72.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,28044,118 48.2%   
Fx outflow Rs m10,87424,484 44.4%   
Net fx Rs m10,40619,634 53.0%   
CASH FLOW
From Operations Rs m13,49570,822 19.1%  
From Investments Rs m-29,103-42,216 68.9%  
From Financial Activity Rs m23,158-22,854 -101.3%  
Net Cashflow Rs m7,5566,107 123.7%  

Share Holding

Indian Promoters % 74.8 63.7 117.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 5.9 23.0 25.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.3 132.5%  
Shareholders   44,069 133,026 33.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  BIOCON LTD  UNICHEM LAB  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 16, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - ABBOTT INDIA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS